Danaher Reports First Quarter 2025 Results

Core Insights - Danaher Corporation reported strong first-quarter results for 2025, with revenue, earnings, and cash flow exceeding expectations, driven by growth in bioprocessing and respiratory demand in molecular diagnostics [2][11] - The company anticipates low-single-digit growth in non-GAAP core revenue for the second quarter and approximately 3% growth for the full year 2025 [4][20] - Adjusted diluted net earnings per common share guidance for the full year 2025 is set in the range of $7.60 to$7.75 [4][20] Financial Performance - For the first quarter ended March 28, 2025, net earnings were $1.0 billion, or$1.32 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $1.88 [11][15] - Revenues decreased by 1.0$5.7 billion, with non-GAAP core revenue remaining flat year-over-year [11][19] - Operating cash flow was reported at $1.3 billion, and non-GAAP free cash flow was$1.1 billion [11][21] Segment Performance - Total sales growth for the company was down 1.0%, with the biotechnology segment growing by 6.0%, while life sciences and diagnostics segments saw declines of 3.5% and 3.0%, respectively [19] - Non-GAAP core sales growth showed a 7.0% increase in biotechnology, while life sciences and diagnostics experienced declines of 4.0% and 1.5% [19] Cash Flow and Investments - The company reported net cash provided by operating activities of $1.3 billion, with total cash used in investing activities at$242 million and financing activities at $1.255 billion [21] - Free cash flow for the quarter was$1.060 billion, down from $1.448 billion in the previous year [21]